Clinical trials in San Donato Milanese – page 83

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

San Donato Milanese at a glance

2 835

clinical trials

Research sites1

Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Plasma cell myeloma

Recruiting

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Contact Research Centre

Prophylaxis of nausea and vomiting

Recruiting

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Contact Research Centre

Crigler-Najjar syndrome

Recruiting

Study on Gene Therapy GNT0003 for Patients with Severe Crigler-Najjar Syndrome Requiring Phototherapy

Registered drugNo placebo

Study on Gene Therapy GNT0003 for Patients with Severe Crigler-Najjar Syndrome Requiring Phototherapy

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Genethon

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Breast cancer metastatic+1

Recruiting

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

InvestigationalNo placebo

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Novartis Pharma AG

Contact Research Centre

Hodgkin's disease

Recruiting

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

Registered drugNo placebo

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Tislelizumab
Sponsor:Fondazione Italiana Linfomi Ets

Contact Research Centre

Haematological malignancy

Recruiting

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:KITE-363
Sponsor:Kite Pharma Inc.

Contact Research Centre

Chronic lymphocytic leukaemia refractory

Recruiting

Study on PTG-CARCIK-CD19 for Adults and Children with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

InvestigationalNo placebo

Study on PTG-CARCIK-CD19 for Adults and Children with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Fondazione Tettamanti

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Juvenile idiopathic arthritis

Recruiting

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Tocilizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

Crohn's Disease Management
Ulcerative Colitis Treatments
Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

Heart Failure Management
Cardiac Surgery Outcomes
Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

Hereditary Angioedema Treatments
Chronic Urticaria Management
Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to Italy All countries